)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
AngioDynamics
AngioDynamics (ANGO) investor relations material
AngioDynamics Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum summary11 Nov, 2026
Leadership and strategic direction
Eric Honroth became CEO on November 2; his initial priorities are action-oriented execution and listening to employees, customers, clinicians and investors.
Cardiovascular, endovascular and oncology remain core focus areas; legacy medical-device products provide earnings and cash to fund MedTech growth investments.
A strategic plan is expected to take shape as the business moves into next year, with investor input informing where to focus resources.
Honroth identified first-year success measures as accelerating MedTech growth and profitability, advancing pivotal clinical trials, and building investor confidence in strategy, team and execution.
Q1 performance and MedTech portfolio
MedTech revenue grew at a 25% CAGR over five years, rising from 17% of revenue when the portfolio strategy began to more than 50% this fiscal year; Q1 growth was double-digit, in line with guidance.
Auryon recorded its 21st consecutive quarter of double-digit growth; management expects the trend to continue over the next several years.
NanoKnife disposables grew 24% YoY in Q1; management remains on track for more than 20% full-year growth in disposables.
AlphaVac grew nearly 40% last year, with growth expected to accelerate this year; AngioVac is expected to be a high-single-digit grower going forward.
Gross-margin performance supported higher EBITDA contribution, while the legacy portfolio continues to fund investment in MedTech growth.
NanoKnife prostate opportunity
Prostate procedures now account for most U.S. NanoKnife procedure volume, and management characterized the market opportunity as still at an early stage.
Reimbursement progress includes a permanent CPT I code effective last January, a positive Palmetto LCD for intermediate-risk prostate patients, and Humana Medicare Advantage adoption of similar coverage language.
Two-year PRESERVE follow-up showed zero recurrences within the intended ablation zone; management plans continued payer outreach, including to other MACs and private insurers.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AngioDynamics
- Board backs two director nominees, auditor ratification, say-on-pay, and an equity plan share increase.ANGO
Proxy filing - Four shareholder votes coincide with a CEO transition and proposed 1M-share plan increase.ANGOProxy filing
- Med Tech-led growth lifted Q1 sales and EBITDA as FY27 guidance held.ANGOQ1 2027
- MedTech growth, platform expansion, and margin gains drive a strong FY27 outlook.ANGOCanaccord Genuity's 46th Annual Growth Conference
- Med Tech drove 18.4% growth and margin gains, with 2027 guidance targeting further expansion.ANGOQ4 2026
- 12.2% revenue growth, 26.1% Med Tech gain, improved margin, and raised FY26 guidance.ANGOQ1 2026
- Transformation to a med tech growth leader is driving profitability and global expansion.ANGO43rd Annual J.P. Morgan Healthcare Conference 2025
- Q3 FY2025 saw 9.2% sales growth, margin expansion, and raised guidance.ANGOQ3 2025
- Q2 FY25 sales up 9.2% YoY, Med Tech up 25%, and profitability outlook raised.ANGOQ2 2025
Next AngioDynamics earnings date
Q2 20275 Jan, 2027
AngioDynamics
Next AngioDynamics earnings date
Q2 20275 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for use by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings in the United States and internationally. The company operates through four segments: Vascular Access, Peripheral Vascular, Oncology/Surgery, and Venous Therapies. The Peripheral Vascular segment primarily offers radiofrequency ablation systems to ablate or destroy undesired tissue; angiographic products to access the vasculature; thrombolytic products to treat clots; embolization products to block blood flow to a tumor; vena cava filters to trap clot before it can travel to the lungs; dialysis catheters used in hemodialysis procedures; and a range of products used in minimally-invasive, image-guided procedures.